Combined CDK4/6 and PI3K alpha Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer

Zhi Ling Teo; Stephanie Versaci; Sathana Dushyanthen; Franco Caramia; Peter Savas; Chris P Mintoff; Magnus Zethoven; Balaji Virassamy; Stephen J Luen; Grant A McArthur; Wayne A Phillips; Phillip K Darcy; Sherene Loi

Journal article

Combined CDK4/6 and PI3K alpha Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer

Zhi Ling Teo, Stephanie Versaci, Sathana Dushyanthen, Franco Caramia, Peter Savas, Chris P Mintoff, Magnus Zethoven, Balaji Virassamy, Stephen J Luen, Grant A McArthur, Wayne A Phillips, Phillip K Darcy, Sherene Loi

Cancer Research | AMER ASSOC CANCER RESEARCH | Published : 2017

DOI: 10.1158/0008-5472.CAN-17-2210

University of Melbourne Researchers

Grant McArthur Author Melbourne Medical School

Phillip Darcy Author The Sir Peter MacCallum Department of Oncology

Zhi Ling Teo Author The Sir Peter MacCallum Department of Oncology

Wayne Phillips Author The Sir Peter MacCallum Department of Oncology

Sherene Loi Author The Sir Peter MacCallum Department of Oncology

Related Projects (3)

COMBINING PI3K, CDK4/6 PATHWAY INHIBITORS AND CHECKPOINT BLOCKADE IN TRIPLE-NEGATIVE BREAST CANCER

Triple-negative breast cancer (TNBC) has the worst prognosis of all breast cancer subtypes, classically affecting young women and characteri..

DETERMINING THE CLINICAL RELEVANCE OF INTRATUMOUR HETEROGENEITY IN BREAST CANCER AND ITS RELATIONSHIP TO METASTASES FORMATION

Breast cancer metastasis is generally an incurable disease, yet it is not well-understood. This project aims to understand how cancer metast..

UTILIZATION OF GENE-ENGINEERED T CELLS FOR ENHANCING CANCER IMMUNOTHERAPY

Killer T lymphocytes can penetrate tumours and their transfer into cancer patients has demonstrated some encouraging results, but this form ..

Grants

Awarded by National Health and Medical Research Council (NHMRC) of Australia

Awarded by NHMRC

Funding Acknowledgements

This work was supported by a National Health and Medical Research Council (NHMRC) of Australia Project Grant (1123208; S. Loi, P.K. Darcy, W.A. Phillips). Z.L. Teo was supported by a NHMRC Early Career Fellowship (1106967). P.K. Darcy was supported by a NHMRC Senior Research Fellowship (1041828). S. Loi was supported by the Cancer Council Victoria Australia John Colebatch Fellowship as well as the Breast Cancer Research Foundation NY. S. Loi has received funding to her institution from Novartis and Pfizer.